Page last updated: 2024-09-04

docetaxel anhydrous and Acquired Immune Deficiency Syndrome

docetaxel anhydrous has been researched along with Acquired Immune Deficiency Syndrome in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hadjiandreou, MM; Mitsis, GD	1
Agarwal, N; Agarwal, P; Baisre, A; Goldstein, IM; Hansberry, DR; Kavi, A	1
Espina, BM; Levine, AM; Lim, ST; Tupule, A	1
Autier, J; Crickx, B; Descamps, V; Grossin, M; Leport, C; Marinho, E; Picard-Dahan, C; Vildé, JL; Yeni, P	1

Trials

1 trial(s) available for docetaxel anhydrous and Acquired Immune Deficiency Syndrome

Article	Year
Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer, 2005, Jan-15, Volume: 103, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Adult; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Risk Assessment; Sarcoma, Kaposi; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2005

Article

Year

Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.

Cancer, 2005, Jan-15, Volume: 103, Issue:2

Topics: Acquired Immunodeficiency Syndrome; Adult; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Risk Assessment; Sarcoma, Kaposi; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome

2005

Other Studies

3 other study(ies) available for docetaxel anhydrous and Acquired Immune Deficiency Syndrome

Article	Year
Taking a break from chemotherapy to fight drug-resistance: The cases of cancer and HIV/AIDS. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2013, Volume: 2013 Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Resistance, Viral; Humans; Mice; Models, Theoretical; Neoplasms; T-Lymphocytes; Taxoids; Tumor Burden	2013
Prognostic Differences: Epstein-Barr Virus-Associated Primary Leiomyosarcoma of the Spine Versus Spinal Leiomyosarcoma Metastases. World neurosurgery, 2017, Volume: 99 Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunocompromised Host; Leiomyosarcoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Prognosis; Retroperitoneal Neoplasms; Spinal Neoplasms; Taxoids	2017
Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study. The British journal of dermatology, 2005, Volume: 152, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; CD4 Lymphocyte Count; Docetaxel; Female; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma, Kaposi; Skin Neoplasms; Taxoids; Treatment Failure; Treatment Outcome	2005